Literature DB >> 26986234

Clinical and therapeutic significance of sirtuin-4 expression in colorectal cancer.

Guoyu Huang1, Jun Cheng1, Fudong Yu2, Xisheng Liu2, Chenwei Yuan2, Chenchen Liu2, Xiaolei Chen1, Zhihai Peng2.   

Abstract

Several members of the sirtuin family (SIRT1-7), which are a highly conserved family of NAD+-dependent enzymes, play an important role in tumor formation. Recent studies indicate that SIRT4 acts as a tumor suppressor by regulating glutamine metabolism. In the present study, we investigated the expression and activity of SIRT4 in colorectal cancer. Using a tissue microarray of 89 colorectal cancer cases, we found that SIRT4 was significantly downregulated in colorectal cancer tissues compared with that noted in the corresponding normal tissue (P<0.001). Lower SIRT4 levels were associated with worse pathological differentiation (P=0.031) and poorer post-operative overall survival rate (P=0.041). We found that SIRT4 overexpression inhibited the proliferation of colorectal cancer cells in vitro and in vivo. SIRT4 inhibited the glutamine metabolism of colorectal cancer cells and synergistically with glycolysis inhibitors induced cell death. SIRT4 also increased the sensitivity of colorectal cancer cells to chemotherapeutic drug 5-fluorouracil by inhibiting the cell cycle. Together, these results highlight the prognostic value of SIRT4 in colorectal cancer and the potential application of SIRT4 in colorectal cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26986234     DOI: 10.3892/or.2016.4685

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  15 in total

1.  The sirtuin family in cancer.

Authors:  Luis Filipe Costa-Machado; Pablo J Fernandez-Marcos
Journal:  Cell Cycle       Date:  2019-07-25       Impact factor: 4.534

Review 2.  Mitochondrial Function, Metabolic Regulation, and Human Disease Viewed through the Prism of Sirtuin 4 (SIRT4) Functions.

Authors:  Cora N Betsinger; Ileana M Cristea
Journal:  J Proteome Res       Date:  2019-04-08       Impact factor: 4.466

3.  SIRT4 functions as a tumor suppressor during prostate cancer by inducing apoptosis and inhibiting glutamine metabolism.

Authors:  Zhuhui Ge; Yunqiu Xu; Guohao Cai; Liangliang Cai; Pingliang Sun; Guoyu Huang
Journal:  Sci Rep       Date:  2022-07-16       Impact factor: 4.996

4.  C-Terminal Binding Protein is Involved in Promoting to the Carcinogenesis of Human Glioma.

Authors:  Bo Liu; Gloria Di
Journal:  Mol Neurobiol       Date:  2016-10-03       Impact factor: 5.590

Review 5.  Sirtuin-4 (SIRT4), a therapeutic target with oncogenic and tumor-suppressive activity in cancer.

Authors:  Guoyu Huang; Guanbao Zhu
Journal:  Onco Targets Ther       Date:  2018-06-11       Impact factor: 4.147

6.  Tumor-suppressive function of SIRT4 in neuroblastoma through mitochondrial damage.

Authors:  Yumei Wang; Yinmou Guo; Jianzhi Gao; Xiangdong Yuan
Journal:  Cancer Manag Res       Date:  2018-11-09       Impact factor: 3.989

7.  SIRT4 inhibits the proliferation, migration, and invasion abilities of thyroid cancer cells by inhibiting glutamine metabolism.

Authors:  Zhouxun Chen; Jiahao Lin; Shuyi Feng; Xuxu Chen; Hanzhang Huang; Chen Wang; Yujun Yu; Yu He; Shaoliang Han; Linfeng Zheng; Guoyu Huang
Journal:  Onco Targets Ther       Date:  2019-03-28       Impact factor: 4.147

Review 8.  Resveratrol's Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism.

Authors:  Aranka Brockmueller; Saba Sameri; Alena Liskova; Kevin Zhai; Elizabeth Varghese; Samson Mathews Samuel; Dietrich Büsselberg; Peter Kubatka; Mehdi Shakibaei
Journal:  Cancers (Basel)       Date:  2021-01-07       Impact factor: 6.639

Review 9.  Nicotinic-nAChR signaling mediates drug resistance in lung cancer.

Authors:  Wan-Li Cheng; Kuan-Yuan Chen; Kang-Yun Lee; Po-Hao Feng; Sheng-Ming Wu
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.478

10.  Loss of SIRT4 promotes the self-renewal of Breast Cancer Stem Cells.

Authors:  Lutao Du; Xiaoyan Liu; Yidan Ren; Juan Li; Peilong Li; Qinlian Jiao; Peng Meng; Fang Wang; Yuli Wang; Yun-Shan Wang; Chuanxin Wang
Journal:  Theranostics       Date:  2020-07-25       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.